Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.41 |
| ▸ | CAMK2A | Q9UQM7 | 3/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 3/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30745861 | 1.00 | EPHX2 (0.45) | EPHX2MAOAMAOBPTGDR2CAMK2A | |
| SCHEMBL3940950 | 0.85 | EPHX2 (0.43) | EPHX2MAOAMAOBPTGDR2PTPN1 | |
| SCHEMBL20562628 | 0.84 | EPHX2 (0.45) | EPHX2MAOAMAOBPTPN1ALPL | |
| SCHEMBL22066846 | 0.81 | SRC (0.50) | PTGDR2CAMK2ARORCRXRARXRB | |
| SCHEMBL12621145 | 0.80 | EPHX2 (0.43) | EPHX2MAOAMAOBPTPN1ALPL | |
| SCHEMBL211400 | 0.80 | EPHX2 (0.43) | EPHX2MAOAMAOBPTGDR2PTPN1 | |
| SCHEMBL30469444 | 0.80 | EPHX2 (0.43) | EPHX2MAOAMAOBPTGDR2PTPN1 | |
| SCHEMBL29383625 | 0.79 | HSD17B10 (0.54) | PTGDR2HSD17B10 | |
| SCHEMBL426773 | 0.79 | HSD17B10 (0.54) | PTGDR2HSD17B10 | |
| SCHEMBL29555215 | 0.78 | EPHX2 (0.41) | EPHX2MAOAMAOBPTPN1ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117682973-A | Sulfonamide compound and medical application thereof | 中国药科大学 | 2024-03-12 | — | — | CN | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | disclosed |
| US-11702396-B2 | Hydrophobic compounds for optically active devices | Johnson & Johnson Surgical Vision, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702396-B2 | Hydrophobic compounds for optically active devices | Johnson & Johnson Surgical Vision, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230203214-A1 | AZACOUMARIN AND AZATHIOCOUMARIN DERIVATIVES FOR USE IN OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203214-A1 | AZACOUMARIN AND AZATHIOCOUMARIN DERIVATIVES FOR USE IN OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-06-29 | — | — | US | disclosed |
| EP-3625227-B1 | BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-14 | — | — | EP | disclosed |
| EP-3728339-B1 | COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS | AMO Ireland (IE) | 2022-07-06 | — | — | EP | disclosed |
| US-11325899-B2 | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-05-10 | — | — | US | disclosed |
| EP-3502147-A1 | COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS | Merck Patent GmbH (DE) | 2019-06-26 | — | — | EP | disclosed |
| WO-2018210987-A1 | BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | disclosed |
| WO-2018210994-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | disclosed |
| WO-2018210988-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | disclosed |
| WO-2017032442-A1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2017-03-02 | — | — | WO | disclosed |
| US-7544690-B2 | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| CN-1582281-A | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO LTD (JP) | 2005-02-16 | — | — | CN | disclosed |
| EP-1432693-A2 | MCH RECEPTOR ANTAGONISTS | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003028641-A2 | MCH RECEPTOR ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | EPHX2 844/4885MAOA 1335/4885MAOB 807/4885 |
| US-11702396-B2 | Hydrophobic compounds for optically active devices | UACA, CRYZ, TRPA1 | EPHX2 605/4885MAOA 2922/4885MAOB 3207/4885 |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | EPHX2 395/4885MAOA 1585/4885MAOB 734/4885 |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | MCHR1, MCHR2, MC4R | EPHX2 3412/4885MAOA 151/4885MAOB 110/4885 |
| US-11325899-B2 | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators | PTGER4, PTGER1, PTGER2 | EPHX2 795/4885MAOA 1219/4885MAOB 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.